Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an update.
Radiopharm Theranostics has disclosed a change in director Ian Turner’s interests in the company’s securities, following shareholder approval at the 20 November 2025 Annual General Meeting. Turner has been issued 6,814,000 additional unlisted options on a non-cash basis pursuant to a shareholder-approved resolution, increasing his total holding to 25,802,350 options (24,981,928 held directly and 820,422 indirectly), while his shareholding remains unchanged at 9,255,292 shares. The issuance reflects ongoing equity-based remuneration and further aligns the director’s incentives with shareholder interests, but does not involve any on-market transactions or changes to contractual interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited (ASX: RAD) is an Australia-listed company operating in the radiopharmaceutical and theranostics sector, focusing on the development and commercialisation of diagnostic and therapeutic products that use targeted radiation for the detection and treatment of disease. The company is positioned within the biotechnology and medical technology market, seeking to leverage advanced nuclear medicine to address significant unmet clinical needs.
Average Trading Volume: 12,079,242
Technical Sentiment Signal: Buy
Current Market Cap: A$99.24M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.